Press Releases

* Mortality risk reduction greater in patients treated for at least 3 years or those with baseline LDL-C levels of at least 100 mg/dL

* Praluent significantly reduced major adverse cardiovascular events by 15% (p<0.001)

-- Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype

- Dupixent significantly reduced nasal polyp size, nasal congestion severity, and need for systemic corticosteroids and/or surgery

* Libtayo is the third anti-PD-1 approved in the U.S.

* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy